Baxter International Inc (BAX)

BAX on New York Consolidated

74.48USD
19 Dec 2014
Price Change (% chg)

$0.41 (+0.55%)
Prev Close
$74.07
Open
$74.07
Day's High
$74.77
Day's Low
$73.37
Volume
3,717,555
Avg. Vol
2,885,645
52-wk High
$77.31
52-wk Low
$66.34

BAX

Chart for BAX

About

Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.... (more)

Overall

Beta: 0.71
Market Cap (Mil.): $40,366.54
Shares Outstanding (Mil.): 541.98
Dividend: 0.52
Yield (%): 2.79

Financials

  BAX Industry Sector
P/E (TTM): 23.27 34.98 38.47
EPS (TTM): 3.20 -- --
ROI: 8.78 10.78 18.25
ROE: 21.64 12.60 19.13
Search Stocks

BRIEF-Caverion provides building systems for Baxter in Austria

* Entered into a contract with pharmaceutical group Baxter in framework of a consortium with Molin

10 Nov 2014

Baxter's blood disorder drug gets FDA approval

- (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)

27 Oct 2014

CORRECTED-UPDATE 1-Baxter's blood disorder drug gets FDA approval (Oct 24)

(Corrects to remove paragraph saying that Obizur will compete with Biogen Idec Inc's Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A)

27 Oct 2014

UPDATE 1-Baxter's blood disorder drug gets FDA approval

Oct 24 - Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.

24 Oct 2014

Baxter's blood disorder drug gets FDA approval

Oct 24 - Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug for treating bleeding episodes in adults with a rare bleeding disorder.

24 Oct 2014

UPDATE 1-AstraZeneca cancer drug pipeline gets boost from European green light

* EMA also backs new drugs from Pfizer, Baxter, Clinuvel (Adds AstraZeneca comment, further details)

24 Oct 2014

Medical products push Baxter profit above estimate

- Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

16 Oct 2014

UPDATE 1-Medical products push Baxter profit above estimate

Oct 16 - Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales in its medical products business continued to grow.

16 Oct 2014

Medical products push Baxter profit above estimate

Oct 16 - Medical device and drug maker Baxter International Inc reported a higher-than-expected quarterly profit, as sales at its medical products business continued to grow.

16 Oct 2014

Baxter plans to open R&D center in Massachusetts for Baxalta spinoff

- Baxter International Inc on Monday said it would form a research and development center in Cambridge, Massachusetts, for the biopharmaceutical business it expects to spin off as a separate company in mid-2015.

29 Sep 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $105.55 -1.26
Pfizer Inc. (PFE.N) $31.94 -0.03
Roche Holding Ltd. (ROG.VX) CHF270.40 -18.30
Abbott Laboratories (ABT.N) $46.05 +0.28
Boston Scientific Corporation (BSX.N) $13.15 -0.11
Wyeth Limited (WLED.NS) Rs1,333.85 --
Hospira, Inc. (HSP.N) $62.66 +0.22

Earnings vs. Estimates

Search Stocks